News
EQS-News: MEDICLIN lädt zur virtuellen Bilanzpressekonferenz 2025 ein
Pfizer Stock: Company Sells Entire Haleon Stake
Pharmaceutical giant Pfizer has divested its complete shareholding in consumer health company Haleon for approximately £2.5 billion ($3.24 billion). The transaction was executed at 385 pence per
ANI Stock: Strategic Move Eliminates Future Royalty Obligations
ANI Pharmaceuticals has made a significant financial move that could substantially improve its future prospects. The pharmaceutical company announced the complete elimination of its royalty
Eli Lilly Stock: Oral Alternative Threatens Market Dominance
Eli Lilly faces a potential challenge to its dominant position in the lucrative GLP-1 market after Lexaria Bioscience Corp. reported breakthrough results with its oral DehydraTECH-tirzepatide
EQS-News: Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 der BRAIN Biotech AG
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?
When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off-label use by celebrities and social media influencers for cutting
Incyte Stock: Breakthrough Drug Shows Promise
Incyte Corporation is poised for significant market growth following positive results from two pivotal Phase 3 trials for Povorcitinib, its oral JAK1 inhibitor targeting Hidradenitis suppurativa
Microvision WA Aktie: Krise absehbar?
Die Aktie des Lidar-Technologiespezialisten Microvision verzeichnete am 17. März 2025 einen Kursanstieg um 2,34% auf 1,31 USD. Trotz dieser positiven Tagesentwicklung bleibt die langfristige Tendenz
Teleflex Aktie: Wettbewerbssituation unverändert
Die Teleflex Aktie verzeichnete am vergangenen Freitag einen moderaten Anstieg von 0,80% und erreichte damit einen Kurs von 126,50 EUR. Diese positive Entwicklung steht im Kontrast zur schwachen
Novartis Stock: Shares Drop Amid Mixed Financial Outlook
Novartis shares experienced a notable decline on Friday at the Swiss SIX exchange, falling 0.7 percent to close at 96.25 CHF. The pharmaceutical stock opened at 96.52 CHF before touching a daily low
Roche Stock: Mixed Signals Amid 40% Recovery
Roche's stock has displayed a mixed performance in recent trading sessions. On Thursday afternoon, shares initially gained 0.5 percent to reach 304.70 CHF on the SIX Swiss Exchange, even touching a
This ETF Has Given Investors a Golden Opportunity
One nice thing about investing with exchange-traded funds is that you're not just limited to stock market investments. There are now ETFs available for a wide array of different asset classes
Is Eli Lilly's Weight Loss Empire in Trouble?
Over the past two years, Eli Lilly (NYSE: LLY) has established itself as the leader in the weight loss market. That's thanks to the company's tirzepatide, a compound sold under the brand name
Is Dentsply Sirona Stock a Buy After a Company Director Purchased 15,000 Shares?
Gregory T. Lucier, a member of the Board of Directors of Dentsply Sirona (NASDAQ:XRAY), reported the purchase of 15,000 shares of common stock at an average price of $12.45 per share on March 9
This Stock Just Jumped By 8%: Is It Too Late to Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) has encountered several clinical setbacks over the past 18 months, including for two products in its growing pain medicine franchise. Even with recent approvals
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline
On February 17, 2026, Deerfield Management Company disclosed a buy of Praxis Precision Medicines (NASDAQ:PRAX), adding 62,500 shares in a trade estimated at $11.64 million based on quarterly average
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings
On February 17, 2026, Driehaus Capital Management disclosed a buy of 432,510 shares of Praxis Precision Medicines (NASDAQ:PRAX), an estimated $80.54 million trade based on quarterly average pricing.
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
On February 17, 2026, Sphera Funds Management Ltd. disclosed a purchase of 374,847 shares of Syndax Pharmaceuticals (NASDAQ:SNDX), an estimated $6.54 million trade based on quarterly average
1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
The wash-out from the COVID-19 pandemic has been brutal for any pharmaceutical stock. Pfizer (NYSE: PFE) has been no exception. As a vaccine maker, Pfizer has faced headwinds to growth in the last
The Best Dividend Stocks to Buy and Hold Forever
Dividend investing is a proven way to grow your wealth over the long run. But for the strategy to work, investors need to pick quality income stocks, those with robust underlying businesses that are
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
A multibagger stock is one that has doubled your money or more. Peter Lynch, the highly respected investment manager who ran the Magellan Fund for 14 years, coined the term in his book, One Up on
Copper Miner Hudbay Soars 200% in a Year as One Investor Exited a $2.5 Million Position
On February 17, 2026, Orion Resource Partners disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold out its position in Hudbay Minerals (NYSE:HBM), with an estimated
SVP Sells Qorvo 8,226 Shares Worth $683,000
Frank P. Stewart, SVP, Advanced Cellular at Qorvo (NASDAQ:QRVO), reported the direct sale of 8,226 shares for a transaction value of approximately $683,000 on Feb. 17, 2026, according to a SEC Form
Here's Why Viking Therapeutics Stock Recovered and Can Soar 2026
Shares in Vikinig Therapeutics (NASDAQ: VKTX) rose by 16.5% in February, according to data from S&P Global Market Intelligence. The move helped the stock recover in 2026, and at the time of writing,
AEVIS VICTORIA SA - Infracore SA publishes audited 2025 consolidated results and AGM proposals
